


## Naloxegol

|                    |   |
|--------------------|---|
| Cat. No.:          | HY-A0118  |
| CAS No.:           | 854601-70-0   |
| Molecular Formula: | C <sub>34</sub> H <sub>53</sub> NO <sub>11</sub>  |
| Molecular Weight:  | 651.78  |
| Target:            | Opioid Receptor   |
| Pathway:           | GPCR/G Protein; Neuronal Signaling  |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                           |  |
|---------------------------|--|
| Description               | Naloxegol (NKTR-118; AZ-13337019) is a $\mu$ -opioid-receptor antagonist. Naloxegol inhibits opioid binding in $\mu$ -opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation <sup>[1][2]</sup> . |
| IC <sub>50</sub> & Target | Opioid receptor <sup>[1]</sup>   |

### CUSTOMER VALIDATION

- Front Immunol. 2021 Jul 7;12:692286.
- Eur J Pharmacol. 2021 Apr 29;174132.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- [1]. Yoon SC, et al. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem. Patient Prefer Adherence. 2017 Jul 24;11:1265-1271.
- [2]. Garnock-Jones KP, et al. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015 Mar;75(4):419-25.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA